Both trials implicate IL-22 in alcoholic hepatitis, with the first studying its biological effects in the disease and the second aiming to use recombinant human IL-22 to take advantage of the anti-steatotic and anti-apoptotic functions of this cytokine. Here, IL22 is linked to alcoholic hepatitis.